JP2015509085A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509085A5
JP2015509085A5 JP2014549632A JP2014549632A JP2015509085A5 JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5 JP 2014549632 A JP2014549632 A JP 2014549632A JP 2014549632 A JP2014549632 A JP 2014549632A JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5
Authority
JP
Japan
Prior art keywords
composition
antibody
endo180
antigen
lipid particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014549632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2012/000405 external-priority patent/WO2013098813A1/en
Publication of JP2015509085A publication Critical patent/JP2015509085A/ja
Publication of JP2015509085A5 publication Critical patent/JP2015509085A5/ja
Pending legal-status Critical Current

Links

JP2014549632A 2012-01-01 2012-12-31 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 Pending JP2015509085A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582373P 2012-01-01 2012-01-01
US61/582,373 2012-01-01
PCT/IL2012/000405 WO2013098813A1 (en) 2012-01-01 2012-12-31 Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
JP2015509085A JP2015509085A (ja) 2015-03-26
JP2015509085A5 true JP2015509085A5 (https=) 2016-02-18

Family

ID=47681993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549632A Pending JP2015509085A (ja) 2012-01-01 2012-12-31 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子

Country Status (7)

Country Link
US (1) US20150216998A1 (https=)
EP (1) EP2797632A1 (https=)
JP (1) JP2015509085A (https=)
CN (1) CN104080480A (https=)
CA (1) CA2858336A1 (https=)
SG (1) SG11201403756PA (https=)
WO (1) WO2013098813A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
EP2839015B1 (en) 2012-04-18 2020-04-29 Ramot at Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US10583084B2 (en) 2014-06-26 2020-03-10 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
EP3237436B1 (en) * 2014-12-24 2019-05-01 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of molecules
WO2016115320A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructructures with core motifs
JP2016160248A (ja) * 2015-03-05 2016-09-05 国立大学法人京都大学 糖誘導体、またはその塩、セレクチン結合剤、糖結合体、粒子状キャリア、および輸送方法
EP4667492A3 (en) * 2015-05-26 2026-04-15 Ramot at Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
CA3252097A1 (en) * 2016-02-05 2026-03-02 The University Of Copenhagen ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
JP7019201B2 (ja) * 2016-08-02 2022-02-15 キュリアールエックス インコーポレーテッド リポソームの調製方法
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
ES2711669A1 (es) * 2017-11-02 2019-05-06 Univ Santiago Compostela Sistemas de liberacion de farmacos de acido polisialico y metodos
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2022041760A1 (en) * 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2024086810A1 (en) * 2022-10-21 2024-04-25 Georgia Tech Research Corporation Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
CA1264668A (en) 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
JP2003528131A (ja) * 2000-03-29 2003-09-24 アラダイム コーポレーション カチオン性リポソーム
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2003260370B2 (en) 2002-08-05 2008-05-22 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
JP2007519394A (ja) 2003-05-19 2007-07-19 クアーク・バイオテック・インコーポレイテッド 疾患の診断および治療のためのｅｎｄｏ１８０受容体の使用
EP1811960A2 (en) * 2004-11-19 2007-08-01 Novosom AG Improvements in or relating to pharmaceutical compositions for local administration
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
AU2007243370A1 (en) 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research, Inc. Method of producing immunoliposomes and compositions thereof
US20130129752A1 (en) 2006-04-25 2013-05-23 Immune Disease Institute, Inc. Targeted delivery to leukocytes using protein carriers
WO2008020435A2 (en) 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
CN102378766A (zh) * 2009-03-23 2012-03-14 夸克医药公司 治疗癌症和纤维化疾病的化合物组合物和方法
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
CN102973506B (zh) * 2011-09-05 2015-06-03 中国科学院深圳先进技术研究院 阳离子脂质体及其制备方法

Similar Documents

Publication Publication Date Title
JP2015509085A5 (https=)
van der Koog et al. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization
Feng et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His
Zhang et al. Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona
US8992984B1 (en) Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
Suk et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier
Varshney et al. Targeted delivery of microRNA‐199a‐3p using self‐assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice
Gujrati et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy
Zarschler et al. Diagnostic nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies
US20110269942A1 (en) Antibodies modified with hydrophobic molecule
US20170173169A1 (en) Cross-linked polymer modified nanoparticles
JP2012100677A5 (https=)
JP2014532071A (ja) カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
JP2014512409A5 (https=)
WO2012094653A2 (en) Compositions and methods for macromolecular drug delivery
JP2022544289A (ja) Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
Kularatne et al. Recruiting cytotoxic T cells to folate-receptor-positive cancer cells
CN110809582B (zh) 涉及抗pd1抗体试剂的方法以及组合物
JP2022544288A (ja) ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物
R. Beech et al. Mechanisms for targeted delivery of nanoparticles in cancer
US20150174265A1 (en) Reversible masking of pore-forming proteins for macromolecular delivery
Chen et al. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG× CD20)
AU2023378958A1 (en) Self-assembling lipid nanoparticles for targeted delivery of therapeutic agents
CN117241804A (zh) 在癌症治疗中slc4a4的抑制
JP2019533677A (ja) 細胞傷害性粒子